Project Grant R41AT013357
Award Date 8/17/26
Completion Date 7/31/27
Dollars Obligated $399K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbia, SC 29229, USA
Similar Awards
- The National Institutes of Health National Center for Complementary and Integrative Health awarded The Leland Stanford Junior University $787,346 on April 13, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to restore key functions to the industrialized gut microbiome. The project characterizes microbial strains capable of fermenting microbiota-accessible carbohydrates (MACs) into short-chain fatty acids (SCFAs)—acetate, propionate, and...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded the University of Florida Division of Sponsored Research $392,142 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanoparticle therapeutics for inflammatory bowel disease. The award funds development of an off-the-shelf therapeutic approach using polysaccharide A (PSA)–derived nanoparticles from commensal...
- This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH) under CFDA Program 93.213 - Research and Training in Complementary and Integrative Health, provides $506,000.00 in funding to the Scripps Research Institute in La Jolla, CA from September 13, 2024 to August 31, 2026. The award supports research to develop orally available recombinant peptidoglycan hydrolase therapeutics that can promote intestinal barrier function and protect against enteric...
- The National Science Foundation awarded Caleo Biotechnologies, Inc. $289,435 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop patient-derived, multicellular tissue models for studying colitis-associated colorectal cancer. The project will generate self-assembling tissue systems that integrate epithelial, stromal, and immune compartments to reproduce inflammation-driven tumor initiation and early progression. The models aim to reduce...
- The National Cancer Institute awarded Lipo-Immuno TECH LLC $348,352 on August 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a C18-ceramide analog drug targeting head and neck squamous cell carcinoma. The recipient is developing LCL768, a first-in-class compound that conjugates C18-ceramide with pyridinium to selectively accumulate in HNSCC mitochondria, bind LC3B, and recruit autophagosomes, with selenite included to induce DRP1 activation and lethal mitophagy....
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $356,328 to Celdara Medical, LLC on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel allogeneic cell therapy for difficult-to-treat inflammatory bowel disease. Celdara will develop cell-based therapeutic candidates targeting the dysregulated immune response in IBD patients who fail multiple lines of conventional therapy or experience...
- The National Center for Complementary and Integrative Health, part of the Department of Health and Human Services National Institutes of Health, awarded $413,972 to Oklahoma State University Center for Health Sciences on August 12, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds investigation of how early life stress triggers imbalances in gut bacterial genera, particularly Roseburia, and influences brain responses through...
- The National Center for Complementary and Integrative Health (NCCIH), part of the U.S. Department of Health and Human Services, awarded a $437,458 Project Grant under CFDA Program 93.213 "Research and Training in Complementary and Integrative Health" to the University of Illinois. The grant will fund a 2-year randomized crossover study exploring the effects of a Mediterranean diet on gut microbiome composition and chronic pain in 24 adults with sickle cell disease. The study aims to...
- This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH) under CFDA 93.213 - Research and Training in Complementary and Integrative Health provides $451,000.00 in funding to The Trustees of Princeton University from September 2024 to August 2026. The objective is to characterize the secondary metabolomes of three Corynebacterial strains, including uncovering the small molecule products they use to compete with other microbes and interact with host cells....
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oral first-in-class small-molecule therapeutics targeting a novel immunometabolic pathway for multiple sclerosis treatment. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will conduct Phase I research validating the safety, efficacy, and...